Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol as an Adjunct to Buprenorphine for Cue-Induced Cravings in Opioid Use Disorder
NCT04192370Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in opioid use disorder (OUD), sponsored by Brigham and Women's Hospital. Primary endpoint: Change in Cue-induced Cravings and Anxiety After 3 Days of Cannabidiol Administration. Started Aug 2020; status: completed.
02
Drugs
cannabidiol
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04192370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192370.